Content about Acura Pharmaceuticals

November 5, 2013

Acura Pharmaceuticals on Monday announced that Nexafed, its next generation pseudoephedrine with abuse-deterrent technology, will now be stocked by Rite Aid.

September 5, 2013

Acura Pharmaceuticals announced a study, published in the September issue of the American Journal of Drug and Alcohol Abuse, that validates the ability of Nexafed to uniquely disrupt the extraction and conversion of pseudoephedrine into methamphetamine.

August 28, 2013

Fruth Pharmacy is taking up a pseudoephedrine product for nasal congestion designed to deter the manufacturing of methamphetamine at all of its stores, according to published reports.

July 15, 2013

Acura Pharmaceuticals on Monday announced a second-generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of methamphetamine hydrochloride when processed in the direct conversion or one-pot method.

March 6, 2013

Acura Pharmaceuticals announced that its next-generation pseudoephedrine with abuse-deterrent technology will now be stocked by North Carolina's Kerr Drug.

December 27, 2012

In support of its December launch of the pseudoehedrine product Nexafed, Acura Pharmaceuticals recently kicked off a national e-mail campaign to help drive pharmacists to the Nexafed website with content specifically designed for the pharmacist audience, including infographics, graphic representations of study data and a behind-the-scenes look at Nexafed's abuse-deterrent technology.

November 15, 2012

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

November 8, 2012

Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that in inhibits the diversion to methamphetamnine.

October 29, 2012

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

January 24, 2012

A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

June 22, 2011

The Food and Drug Administration has approved a medication designed to treat acute and chronic moderate to severe pain, where the use of an opioid analgesic is suitable.

February 14, 2011

The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

December 20, 2010

Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

© 2014 Drug Store News. All Rights Reserved.